NYSE:AZN AstraZeneca - AZN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. $63.76 +0.61 (+0.97%) (As of 02/3/2023 10:32 AM ET) Add Share Share Today's Range$63.37▼$64.0950-Day Range N/A52-Week Range$52.65▼$72.12Volume1.24 million shsAverage Volume6.07 million shsMarket Capitalization$197.58 billionP/E RatioN/ADividend Yield1.38%Price TargetN/A ProfileChartCompetitorsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media About AstraZeneca (NYSE:AZN) StockAstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. These pharmaceutical products are then manufactured, marketed and sold. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.Read More Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Stock News HeadlinesJanuary 30, 2023 | marketbeat.comCassava Sciences Stock Undervalued with Its $124 Price Target? (AZN)Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is aFebruary 2, 2023 | stocknews.com3 Pharma Stocks to Buy in 2023 and Hold for DecadesFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.February 2, 2023 | markets.businessinsider.comAstraZeneca, Amgen's Tezspire Pre-filled Pen Receives FDA Approval In US For AsthmaJanuary 30, 2023 | finance.yahoo.comIs AstraZeneca PLC (AZN) a High Growth Stock?January 30, 2023 | americanbankingnews.comAstraZeneca (NYSE:AZN) Raised to Strong-Buy at StockNews.comJanuary 26, 2023 | reuters.comU.S. FDA withdraws authorization for AstraZeneca's EvusheldJanuary 26, 2023 | msn.comAstraZeneca COVID-19 therapy no longer authorized in U.S.February 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 26, 2023 | reuters.comU.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment EvusheldJanuary 26, 2023 | bizjournals.comCinCor CEO: acquisition by AstraZeneca was more than a year in the makingJanuary 25, 2023 | marketwatch.comAstraZeneca rises Wednesday, outperforms marketJanuary 25, 2023 | stocknews.com2 Pharma Stocks to Buy Now for Big Gains in 2023January 24, 2023 | marketwatch.comAstraZeneca PLC ADR underperforms Tuesday when compared to competitorsJanuary 24, 2023 | marketwatch.comAstraZeneca falls Tuesday, underperforms marketJanuary 23, 2023 | msn.comCytoSorbents says Canada cleared pivotal study for anti-bleeding technologyDecember 9, 2022 | markets.businessinsider.comAstraZeneca: Datopotamab Deruxtecan Shows Encouraging Objective Response Rate In Phase I TrialDecember 8, 2022 | seekingalpha.comNovartis iptacopan comes out successful in 2nd phase 3 trial rare blood disorderDecember 8, 2022 | markets.businessinsider.comAZN:Phase III Trial Of Capivasertib Combination Shows Improvement In PFS In Metastatic Breast CancerDecember 8, 2022 | markets.businessinsider.comAZN:Camizestrant Delayed Disease Progression In Advanced ER-Positive Breast Cancer In Phase II TrialDecember 5, 2022 | stocknews.com5 Amazing Stocks You Won’t Ever Regret BuyingDecember 1, 2022 | reuters.comAstraZeneca boosts cancer portfolio with $320 mln Neogene dealNovember 30, 2022 | reuters.comAstraZeneca to sell Ohio site to biotech firm ResilienceNovember 30, 2022 | proactiveinvestors.comAstraZeneca sells Ohio manufacturing plant to National ResilienceNovember 29, 2022 | bizjournals.comRNA startup led by Pfizer vets closes $52M investment roundNovember 28, 2022 | bizjournals.comAstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402MNovember 21, 2022 | finance.yahoo.comHere’s Why AstraZeneca PLC (AZN) Declined in the Third QuarterSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceuticals: Major Sub-IndustryN/A SectorHealth Technology Current SymbolNYSE:AZN CUSIPN/A CIK901832 WebN/A Phone442037495000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,098,840,000Free FloatN/AMarket Cap$197.58 billion OptionableOptionable BetaN/A Key ExecutivesPascal SoriotChief Executive Officer & Executive DirectorPam P. ChengExecutive VP-Operations & Information TechnologyAradhana SarinChief Financial Officer & Executive DirectorMenelas NICOLAS PangalosEVP-Biopharmaceuticals Research & DevelopmentCindy L. HootsChief Digital & Information Officer AZN Stock - Frequently Asked Questions How have AZN shares performed in 2023? AstraZeneca's stock was trading at $69.15 at the beginning of 2023. Since then, AZN stock has decreased by 8.7% and is now trading at $63.15. View the best growth stocks for 2023 here. Is AstraZeneca a good dividend stock? AstraZeneca (NYSE:AZN) pays an annual dividend of $0.91 per share and currently has a dividend yield of 1.38%. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Moderna (MRNA), Tesla (TSLA), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Walmart (WMT). What is AstraZeneca's stock symbol? AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN." How do I buy shares of AstraZeneca? Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AstraZeneca's stock price today? One share of AZN stock can currently be purchased for approximately $63.15. How much money does AstraZeneca make? AstraZeneca (NYSE:AZN) has a market capitalization of $195.69 billion. How can I contact AstraZeneca? The company can be reached via phone at 442037495000. This page (NYSE:AZN) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.